Compare Abbott Laboratories (ABT) vs Dell Technologies Inc (DELL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Dell Technologies Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Dell Technologies Inc trades at $430.95 (market cap $269.62B). The key difference: Dell Technologies Inc is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | DELL | |
|---|---|---|
Market Cap | $166.94B | $269.62B |
Sector | Health | Technology |
52-Week High | $136.62 | $466.02 |
52-Week Low | $82.57 | $111.10 |
Enterprise Value | $193.69B | $289.21B |
Dividend Yield | 2.63% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Dell Technologies trades at $416.98, up 5.75% in the last 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $484.28. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $4.86 surpassing the $2.96 estimate. The company shows strong revenue growth projections to $134 billion in 2026 and benefits from AI server demand, though net cash flow was negative $3.69 billion in 2025.
The outlook for Dell is positive, driven by AI infrastructure dominance and expanding profit margins, but risks include supply constraints, competitive pressures, and negative shareholder equity. With 57.8% of analysts rating it a buy, the stock offers growth potential, yet investors should weigh execution risks against the robust AI-driven revenue backlog.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →
